Kuo-Cheng Wu
Overview
Explore the profile of Kuo-Cheng Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu K, Lee I, Liu C, Chiu N, Hsu S, Lee P, et al.
J Hepatocell Carcinoma
. 2024 Nov;
11:2257-2267.
PMID: 39588492
Purpose: Diabetes mellitus (DM) negatively impacts chronic hepatitis B patients, but its role in those with HBV-related hepatocellular carcinoma (HCC) undergoing ablation remains unclear. This study aims to evaluate the...
2.
3.
Wu K, Lee I, Chi C, Liu C, Chiu N, Hsu S, et al.
Aliment Pharmacol Ther
. 2024 Aug;
60(7):940-952.
PMID: 39113355
Background: The benefits of HCV eradication on distinct recurrence patterns and long-term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to...
4.
Wu K, Lee Y, Chen S
Front Psychol
. 2024 Jul;
15:1415693.
PMID: 39021653
Introduction: This study aimed to examine perceptual-cognitive skills across age, gender and elite levels of badminton adolescent athletes. Methods: A total of 57 badminton athletes divided into junior high school...
5.
Lee I, Chao Y, Lee P, Chen S, Chi C, Wu C, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454919
The predictors of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and...
6.
Wu K, Lee I, Chi C, Lei H, Chau G, Yeh Y, et al.
Am J Cancer Res
. 2021 Dec;
11(11):5526-5542.
PMID: 34873477
Whether direct-acting antivirals (DAA) provide comparable survival benefit with interferon (IFN)-based therapy remains unclear. The aim of this study was to compare the outcomes after achieving SVR by IFN-based and...
7.
Wu K, Huang H, Chang T, Lee W, Chuang C, Hsin I, et al.
Eur J Pharmacol
. 2018 Feb;
824:133-139.
PMID: 29444470
Cirrhosis is often associated with portal hypertension and portal-systemic collateral vessels formation attributed to angiogenesis, which leads to severe complications as hepatic encephalopathy. Sirolimus has anti-fibrosis and anti-angiogenesis effects, but...